Atara Biotherapeutics (ATRA) Free Cash Flow (2013 - 2026)
Atara Biotherapeutics' (ATRA) quarterly Free Cash Flow came in at -$3.1 million in Q1 2026, up 89.08% YoY from -$1.6 million in Q1 2025, and up 46.06% on a QoQ basis from -$5.7 million in Q4 2025.
Atara Biotherapeutics (ATRA) Free Cash Flow (2013 - 2026) Analysis & Trends
Atara Biotherapeutics (ATRA) has 14 years of Free Cash Flow data on file, last reported at -$3.1 million in Q1 2026.
- Quarterly Free Cash Flow rose 89.08% year-over-year to -$3.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$25.9 million (up 61.66% YoY) and the FY2025 annual result came in at -$50.9 million, up 26.13% from the prior year.
- Free Cash Flow grew to -$3.1 million in Q1 2026, from -$5.7 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$3.1 million in Q1 2026 to a low of -$87.1 million in Q1 2022.
- A 5-year average of -$34.4 million and a median of -$29.6 million in 2024 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2024 — Free Cash Flow surged 92.27% — and 2025, when it sank 145.35%.
- Tracing ATRA's Free Cash Flow over 5 years: stood at -$56.9 million in 2022, then advanced by 15.33% to -$48.2 million in 2023, then jumped by 49.03% to -$24.6 million in 2024, then surged by 76.8% to -$5.7 million in 2025, then jumped by 46.06% to -$3.1 million in 2026.
- The last three Free Cash Flow figures came in at -$3.1 million (Q1 2026), -$5.7 million (Q4 2025), and -$9.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Atara Biotherapeutics | 141.08 Mn | 124.53 Mn | 439,000.00 | -3.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.34 Mn |
| Jun 30, 2026 | -3.34 Mn |
| Mar 31, 2026 | -3.07 Mn |
| Mar 31, 2026 | -3.07 Mn |
| Dec 31, 2025 | -5.70 Mn |
| Dec 31, 2025 | -5.70 Mn |
| Sep 30, 2025 | -9.79 Mn |
| Sep 30, 2025 | -9.79 Mn |
| Jun 30, 2025 | -7.32 Mn |
| Jun 30, 2025 | -7.32 Mn |
| Mar 31, 2025 | -28.14 Mn |
| Mar 31, 2025 | -28.14 Mn |
| Dec 31, 2024 | -24.56 Mn |
| Dec 31, 2024 | -24.56 Mn |
| Sep 30, 2024 | -3.99 Mn |
| Sep 30, 2024 | -3.99 Mn |
| Jun 30, 2024 | -10.80 Mn |
| Jun 30, 2024 | -10.80 Mn |
| Mar 31, 2024 | -29.61 Mn |
| Mar 31, 2024 | -29.61 Mn |